2021 Q4 Form 10-Q Financial Statement
#000161883521000240 Filed on November 15, 2021
Income Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
Revenue | $3.570M | $1.712M | $278.0K |
YoY Change | 2000.0% | 515.83% | |
Cost Of Revenue | $1.755M | $955.0K | $317.0K |
YoY Change | 602.0% | 201.26% | |
Gross Profit | $1.815M | $757.0K | -$39.00K |
YoY Change | -2368.75% | -2041.03% | |
Gross Profit Margin | 50.84% | 44.22% | -14.03% |
Selling, General & Admin | $30.57M | $35.43M | $21.90M |
YoY Change | 2.19% | 61.76% | 153.65% |
% of Gross Profit | 1684.52% | 4679.66% | |
Research & Development | $8.659M | $8.701M | $4.217M |
YoY Change | 45.53% | 106.33% | -25.53% |
% of Gross Profit | 477.08% | 1149.41% | |
Depreciation & Amortization | $285.0K | $268.0K | $60.00K |
YoY Change | 137.5% | 346.67% | -14.29% |
% of Gross Profit | 15.7% | 35.4% | |
Operating Expenses | $39.23M | $45.08M | $26.43M |
YoY Change | 9.38% | 70.54% | 84.89% |
Operating Profit | -$37.42M | -$43.37M | -$26.16M |
YoY Change | 4.08% | 65.81% | 82.95% |
Interest Expense | -$12.92M | -$29.50M | -$3.080M |
YoY Change | 252.02% | 857.86% | -1566.67% |
% of Operating Profit | |||
Other Income/Expense, Net | -$1.211M | -$30.69M | -$3.741M |
YoY Change | 13.18% | 720.42% | -849.7% |
Pretax Income | -$51.55M | -$74.06M | -$29.90M |
YoY Change | 26.97% | 147.72% | 116.68% |
Income Tax | $6.000K | $0.00 | $2.000K |
% Of Pretax Income | |||
Net Earnings | -$51.55M | -$74.06M | -$29.90M |
YoY Change | 26.98% | 147.7% | 116.69% |
Net Earnings / Revenue | -1444.09% | -4325.99% | -10755.04% |
Basic Earnings Per Share | -$0.48 | -$0.37 | |
Diluted Earnings Per Share | -$4.786M | -$0.48 | -$0.37 |
COMMON SHARES | |||
Basic Shares Outstanding | 163.1M shares | 154.3M shares | 81.21M shares |
Diluted Shares Outstanding | 154.3M shares | 81.21M shares |
Balance Sheet
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $7.732M | $14.86M | $86.70M |
YoY Change | -84.19% | -82.87% | 142.18% |
Cash & Equivalents | $7.732M | $14.86M | $86.70M |
Short-Term Investments | $100.0K | ||
Other Short-Term Assets | $8.285M | $25.92M | $10.50M |
YoY Change | -79.49% | 146.88% | 600.0% |
Inventory | $7.915M | $9.947M | $3.164M |
Prepaid Expenses | |||
Receivables | $6.449M | $4.031M | $1.243M |
Other Receivables | $0.00 | $147.0K | $500.0K |
Total Short-Term Assets | $30.14M | $54.90M | $102.1M |
YoY Change | -69.16% | -46.22% | 171.98% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $5.774M | $5.769M | $1.976M |
YoY Change | 33.23% | 191.95% | 261.9% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $1.203M | $991.0K | $1.074M |
YoY Change | 14.79% | -7.73% | 80.2% |
Total Long-Term Assets | $12.37M | $12.52M | $10.25M |
YoY Change | 1.09% | 22.21% | 603.36% |
TOTAL ASSETS | |||
Total Short-Term Assets | $30.14M | $54.90M | $102.1M |
Total Long-Term Assets | $12.37M | $12.52M | $10.25M |
Total Assets | $42.51M | $67.43M | $112.3M |
YoY Change | -61.34% | -39.97% | 188.1% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $10.32M | $6.788M | $5.427M |
YoY Change | -3.05% | 25.08% | 5.11% |
Accrued Expenses | $8.370M | $9.022M | $4.607M |
YoY Change | 87.0% | 95.83% | -28.61% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $48.10M |
YoY Change | -100.0% | -100.0% | |
Long-Term Debt Due | $108.9M | $68.72M | |
YoY Change | |||
Total Short-Term Liabilities | $137.7M | $94.69M | $65.69M |
YoY Change | 78.13% | 44.14% | 340.47% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $26.70M | $0.00 |
YoY Change | -100.0% | ||
Other Long-Term Liabilities | $4.424M | $4.871M | $6.400M |
YoY Change | -27.48% | -23.89% | |
Total Long-Term Liabilities | $4.424M | $31.57M | $6.400M |
YoY Change | -85.87% | 393.23% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $137.7M | $94.69M | $65.69M |
Total Long-Term Liabilities | $4.424M | $31.57M | $6.400M |
Total Liabilities | $142.1M | $126.3M | $72.12M |
YoY Change | 30.81% | 75.07% | 383.55% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$860.7M | -$809.1M | -$614.9M |
YoY Change | 31.3% | 31.58% | 22.86% |
Common Stock | $751.3M | $745.2M | $655.1M |
YoY Change | 14.38% | 13.76% | 24.89% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$104.3M | -$58.83M | $40.21M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $42.51M | $67.43M | $112.3M |
YoY Change | -61.34% | -39.97% | 188.1% |
Cashflow Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$51.55M | -$74.06M | -$29.90M |
YoY Change | 26.98% | 147.7% | 116.69% |
Depreciation, Depletion And Amortization | $285.0K | $268.0K | $60.00K |
YoY Change | 137.5% | 346.67% | -14.29% |
Cash From Operating Activities | -$21.27M | -$37.37M | -$35.82M |
YoY Change | -45.59% | 4.32% | 148.4% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$53.00K | -$597.0K | -$830.0K |
YoY Change | -96.27% | -28.07% | 4050.0% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | $530.0K |
YoY Change | -100.0% | -114.25% | |
Cash From Investing Activities | -$53.00K | -$597.0K | -$300.0K |
YoY Change | -96.27% | 99.0% | -91.98% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 9.866M | 16.00K | -600.0K |
YoY Change | -60.41% | -102.67% | 42.86% |
NET CHANGE | |||
Cash From Operating Activities | -21.27M | -37.37M | -35.82M |
Cash From Investing Activities | -53.00K | -597.0K | -300.0K |
Cash From Financing Activities | 9.866M | 16.00K | -600.0K |
Net Change In Cash | -11.45M | -37.95M | -36.72M |
YoY Change | -26.5% | 3.34% | 97.63% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$21.27M | -$37.37M | -$35.82M |
Capital Expenditures | -$53.00K | -$597.0K | -$830.0K |
Free Cash Flow | -$21.21M | -$36.77M | -$34.99M |
YoY Change | -43.67% | 5.09% | 142.99% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001618835 | ||
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | |
us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | ||
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | |
us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | ||
CY2021Q3 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | |
us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | ||
us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | ||
CY2020Q3 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2021-01-31#ProductMember | |
CY2020Q2 | evfm |
Class Of Warrant Or Right Vesting Term
ClassOfWarrantOrRightVestingTerm
|
P5Y | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Local Phone Number
LocalPhoneNumber
|
550-1900 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-36754 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
EVOFEM BIOSCIENCES, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-8527075 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
12400 High Bluff Drive | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 600 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92130 | ||
dei |
City Area Code
CityAreaCode
|
858 | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
163144964 | shares |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14856000 | USD |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48892000 | USD |
CY2021Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
9384000 | USD |
CY2020Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
22559000 | USD |
CY2021Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4031000 | USD |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1067000 | USD |
CY2021Q3 | us-gaap |
Inventory Net
InventoryNet
|
9947000 | USD |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
7162000 | USD |
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16685000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18050000 | USD |
CY2021Q3 | us-gaap |
Assets Current
AssetsCurrent
|
54903000 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
97730000 | USD |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5769000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4334000 | USD |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5764000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
6856000 | USD |
CY2021Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
991000 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1048000 | USD |
CY2021Q3 | us-gaap |
Assets
Assets
|
67427000 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
109968000 | USD |
CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6788000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10641000 | USD |
CY2021Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
68724000 | USD |
CY2020Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
52409000 | USD |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9022000 | USD |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4476000 | USD |
CY2021Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5253000 | USD |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6514000 | USD |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2418000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2290000 | USD |
CY2021Q3 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
26696000 | USD |
CY2020Q4 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
25211000 | USD |
CY2021Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
2482000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
953000 | USD |
CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
94687000 | USD |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
77283000 | USD |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4774000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
6030000 | USD |
CY2021Q3 | us-gaap |
Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
|
97000 | USD |
CY2020Q4 | us-gaap |
Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
|
97000 | USD |
CY2021Q3 | us-gaap |
Liabilities
Liabilities
|
126254000 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
108621000 | USD |
CY2021Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2021Q3 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
5000000 | shares |
CY2021Q3 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
5000000 | shares |
CY2021Q3 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
0 | shares |
CY2021Q3 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | shares |
CY2020Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | shares |
CY2020Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
0 | shares |
CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
CY2021Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
CY2021Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
155208456 | shares |
CY2021Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
155208456 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
81351533 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
81351533 | shares |
CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
16000 | USD |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
8000 | USD |
CY2021Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
745194000 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
656827000 | USD |
CY2021Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
5089000 | USD |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-809126000 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-655488000 | USD |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-58827000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1347000 | USD |
CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
67427000 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
109968000 | USD |
CY2021Q3 | us-gaap |
Revenues
Revenues
|
1712000 | USD |
CY2020Q3 | us-gaap |
Revenues
Revenues
|
278000 | USD |
CY2020Q3 | us-gaap |
Revenues
Revenues
|
278000 | USD |
us-gaap |
Revenues
Revenues
|
4674000 | USD | |
us-gaap |
Revenues
Revenues
|
278000 | USD | |
CY2021Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
955000 | USD |
CY2020Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
317000 | USD |
CY2020Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
317000 | USD |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2300000 | USD | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
317000 | USD | |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8701000 | USD |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4217000 | USD |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4217000 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24470000 | USD | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11104000 | USD | |
CY2021Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
30468000 | USD |
CY2020Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
14700000 | USD |
CY2020Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
14700000 | USD |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
88230000 | USD | |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
32553000 | USD | |
CY2021Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4957000 | USD |
CY2020Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7200000 | USD |
CY2020Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7200000 | USD |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
19057000 | USD | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
24077000 | USD | |
CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
45081000 | USD |
CY2020Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
26434000 | USD |
CY2020Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
26434000 | USD |
us-gaap |
Operating Expenses
OperatingExpenses
|
134057000 | USD | |
us-gaap |
Operating Expenses
OperatingExpenses
|
68051000 | USD | |
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-43369000 | USD |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-26156000 | USD |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-26156000 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-129383000 | USD | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-67773000 | USD | |
CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3000 | USD |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
21000 | USD |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
21000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
14000 | USD | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
152000 | USD | |
CY2021Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1190000 | USD |
CY2020Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-657000 | USD |
CY2020Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-657000 | USD |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-3521000 | USD | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1010000 | USD | |
CY2021Q3 | evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
0 | USD |
CY2020Q3 | evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
0 | USD |
evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
0 | USD | |
evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
64049000 | USD | |
CY2021Q3 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-29505000 | USD |
CY2020Q3 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-3105000 | USD |
us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-20737000 | USD | |
us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
30971000 | USD | |
CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-30692000 | USD |
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3741000 | USD |
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3741000 | USD |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-24244000 | USD | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-33936000 | USD | |
CY2021Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-74061000 | USD |
CY2020Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-29897000 | USD |
CY2020Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-29897000 | USD |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-153627000 | USD | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-101709000 | USD | |
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | USD |
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | USD |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
11000 | USD | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | USD | |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74061000 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29899000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-153638000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-101711000 | USD | |
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.48 | |
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.48 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.37 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.37 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.37 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.27 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.27 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.63 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.63 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
154265434 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
154265434 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
81206101 | shares |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
81206101 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
120691057 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
120691057 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62434949 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
62434949 | shares | |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74061000 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29899000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-153638000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-101711000 | USD | |
CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
5089000 | USD |
CY2020Q3 | us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
0 | USD |
us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
5089000 | USD | |
us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
0 | USD | |
CY2021Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-68972000 | USD |
CY2020Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-29899000 | USD |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-148549000 | USD | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-101711000 | USD | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1347000 | USD |
CY2021Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
7000 | USD |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3464000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-46151000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-13638000 | USD |
CY2021Q2 | evfm |
Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options
StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions
|
196000 | USD |
CY2021Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
300000 | USD |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2993000 | USD |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33426000 | USD |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8964000 | USD |
CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
5089000 | USD |
CY2021Q3 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
20000 | USD |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1091000 | USD |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74061000 | USD |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-58827000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
15636000 | USD |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
73000 | USD |
CY2020Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
25000 | USD |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3401000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19146000 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1021000 | USD |
CY2020Q2 | evfm |
Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options
StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions
|
177000 | USD |
CY2020Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
2777000 | USD |
CY2020Q2 | evfm |
Short Swing Profit Disgorgement
ShortSwingProfitDisgorgement
|
187000 | USD |
CY2020Q2 | evfm |
Adjustments To Additional Paid In Capital Reclassification Of Warrants And Purchase Rights Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsAndPurchaseRightsLiability
|
11015000 | USD |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6034000 | USD |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-52666000 | USD |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68539000 | USD |
CY2020Q3 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
67000 | USD |
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1637000 | USD |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29899000 | USD |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
40210000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-153638000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-101711000 | USD | |
evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
0 | USD | |
evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
64049000 | USD | |
us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-20737000 | USD | |
us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
30971000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7548000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11072000 | USD | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
738000 | USD | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
181000 | USD | |
us-gaap |
Lease Cost
LeaseCost
|
1035000 | USD | |
us-gaap |
Lease Cost
LeaseCost
|
542000 | USD | |
us-gaap |
Interest Expense
InterestExpense
|
2152000 | USD | |
us-gaap |
Interest Expense
InterestExpense
|
992000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2964000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1243000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1908000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2912000 | USD | |
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
196000 | USD | |
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
337000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2636000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
833000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
7650000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
81534000 | USD | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
103738000 | USD | |
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
159000 | USD | |
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2000 | USD | |
evfm |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
0 | USD | |
evfm |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
3781000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-486000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
9070000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3252000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-505000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
5996000 | USD | |
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2900000 | USD | |
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-1261000 | USD | |
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
1283000 | USD | |
evfm |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
1071000 | USD | |
evfm |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
357000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-125402000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-65750000 | USD | |
us-gaap |
Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
|
250000 | USD | |
us-gaap |
Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
|
250000 | USD | |
us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
0 | USD | |
us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
8233000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2886000 | USD | |
us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | USD | |
us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
25000000 | USD | |
evfm |
Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
|
0 | USD | |
evfm |
Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
|
187000 | USD | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
735000 | USD | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
867000 | USD | |
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
327000 | USD | |
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
2869000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
80827000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
129309000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-47211000 | USD | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
71209000 | USD | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
72251000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
16625000 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25040000 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
87834000 | USD |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | USD | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
7618000 | USD | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
714000 | USD | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
73000 | USD | |
evfm |
Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
|
0 | USD | |
evfm |
Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
|
11015000 | USD | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14856000 | USD |
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
86697000 | USD |
CY2021Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
9384000 | USD |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use assets and lease liabilities, the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></div> | ||
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment | |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></div>The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. | ||
CY2020Q4 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
25000000 | USD |
CY2020Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
103700000 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
14900000 | USD |
us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
81500000 | USD | |
CY2021Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
9000000 | USD |
CY2021Q3 | evfm |
Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
|
-39800000 | USD |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-809100000 | USD |
CY2021Q3 | evfm |
Product Revenue Variable Consideration Liability Current
ProductRevenueVariableConsiderationLiabilityCurrent
|
2500000 | USD |
CY2020Q2 | evfm |
Securities Sold Under Purchase Agreement
SecuritiesSoldUnderPurchaseAgreement
|
15000000 | USD |
CY2020Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
337000 | USD |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25040000 | USD |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
87834000 | USD |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
79686738 | shares | |
CY2021Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
79686738 | shares |
CY2020Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19532661 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19532661 | shares | |
CY2021Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
498000 | USD |
CY2020Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
332000 | USD |
CY2021Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
2095000 | USD |
CY2020Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
4162000 | USD |
CY2021Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
7354000 | USD |
CY2020Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2668000 | USD |
CY2021Q3 | us-gaap |
Inventory Gross
InventoryGross
|
9947000 | USD |
CY2020Q4 | us-gaap |
Inventory Gross
InventoryGross
|
7162000 | USD |
CY2020Q2 | evfm |
Securities Sold Under Purchase Agreement
SecuritiesSoldUnderPurchaseAgreement
|
10000000 | USD |
CY2020Q2 | evfm |
Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
|
10000000 | USD |
CY2020Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
2.44 | |
CY2020Q2 | us-gaap |
Convertible Notes Payable
ConvertibleNotesPayable
|
58100000 | USD |
CY2020Q2 | evfm |
Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities
PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities
|
100000000 | USD |
CY2020Q2 | evfm |
Class Of Warrant Or Right Liability
ClassOfWarrantOrRightLiability
|
46700000 | USD |
CY2020Q2 | evfm |
Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
|
64000000 | USD |
CY2020Q2 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
34100000 | USD |
CY2020Q2 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
34100000 | USD |
CY2020Q2 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
34100000 | USD |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
|
15800000 | USD |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
|
11000000 | USD |
CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
|
5100000 | USD |
CY2021Q3 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-29500000 | USD |
CY2021Q3 | evfm |
Debt Instrument Restrictive Covenants Cumulative Net Sales Requirement
DebtInstrumentRestrictiveCovenantsCumulativeNetSalesRequirement
|
100000000 | USD |
CY2021Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
68700000 | USD |
CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1889000 | USD |
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16685000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18050000 | USD |
CY2016Q3 | us-gaap |
Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
|
1900000 | USD |
CY2016Q3 | us-gaap |
Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
|
600000 | USD |
CY2016Q3 | us-gaap |
Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
|
1300000 | USD |
CY2016Q3 | evfm |
Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate
|
0.050 | |
CY2016Q3 | evfm |
Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment
|
300000 | USD |
CY2021Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7658000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5485000 | USD |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1151000 | USD |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
5769000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4334000 | USD |
CY2021Q3 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
200000 | USD |
CY2020Q3 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
100000 | USD |
us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
700000 | USD | |
us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
200000 | USD | |
CY2021Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
800000 | USD |
CY2020Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
800000 | USD |
CY2021Q3 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
136000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
214000 | USD |
CY2021Q3 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
55000 | USD |
CY2020Q4 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
34000 | USD |
CY2021Q3 | us-gaap |
Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
|
991000 | USD |
CY2020Q4 | us-gaap |
Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
|
1048000 | USD |
CY2021Q3 | evfm |
Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
|
5577000 | USD |
CY2020Q4 | evfm |
Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
|
1417000 | USD |
CY2021Q3 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
2320000 | USD |
CY2021Q3 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
22746000 | USD |
CY2021Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
614000 | USD |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
366000 | USD |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9022000 | USD |
CY2020Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
564000 | USD |
CY2021Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
301000 | USD |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1631000 | USD |
CY2021Q3 | evfm |
Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
|
210000 | USD |
CY2020Q4 | evfm |
Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
|
498000 | USD |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4476000 | USD |
CY2021Q3 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
68724000 | USD |
CY2021Q3 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
68724000 | USD |
CY2021Q3 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
68724000 | USD |
CY2020Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
70233000 | USD |
CY2020Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
50752000 | USD |
CY2020Q4 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
50752000 | USD |
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
2300000 | USD | |
CY2021Q3 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
2300000 | USD |
CY2020Q2 | evfm |
Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
|
10000000 | USD |
evfm |
Lessee Operating Lease Number Of Vehicles Leased
LesseeOperatingLeaseNumberOfVehiclesLeased
|
72 | vehicle | |
CY2019Q4 | evfm |
Office Square Footage
OfficeSquareFootage
|
24474 | sqft |
CY2019Q4 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
CY2020Q2 | evfm |
Office Square Footage
OfficeSquareFootage
|
8816 | sqft |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
649000 | USD |
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
583000 | USD |
CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
466000 | USD |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1760000 | USD | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
998000 | USD | |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y9M14D | |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y5M4D | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.12 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.12 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
2480000 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2163000 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2192000 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1502000 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
8986000 | USD |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1794000 | USD |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
7192000 | USD |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1779000 | USD | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
552000 | USD | |
CY2021Q3 | us-gaap |
Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
|
0 | claim |
CY2020Q4 | us-gaap |
Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
|
0 | claim |
CY2019Q2 | evfm |
Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned
CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned
|
1 | |
CY2021Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
67767107 | shares |
CY2021Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.54 | |
CY2021Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
67767107 | shares |
CY2018Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | shares |
CY2018Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q3 | evfm |
Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
|
67767107 | shares |
CY2021Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
83069895 | shares |
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1091000 | USD |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1637000 | USD |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7548000 | USD | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11072000 | USD | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
70000 | shares |
CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
631200 | shares |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
3126525 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2873685 | shares |